Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

REALM THERAPEUTICS PLC (PURI)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
43(c) 43(c) 43(c) 43(c) 43(c) Last
0 0 1 573 5 000 0 Volume
0.00% 0.00% 0.00% 0.00% 0.00% Change
More quotes
Financials ( GBP)
Sales 2017 0,72 M
EBIT 2017 -
Net income 2017 -
Finance 2017 25,1 M
Yield 2017 -
Sales 2018 0,76 M
EBIT 2018 -
Net income 2018 -
Finance 2018 25,3 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 34,5x
EV / Sales2018 32,4x
Capitalization 49,9 M
More Financials
Company
Realm Therapeutics Plc is a clinical stage biopharmaceutical company focused on developing novel immunomodulatory therapies.It operates through two segments: Company and Other and Health Science.The Company and Other segment include costs associated with operating Realm Therapeutics plc, and... 
More about the company
Latest news on REALM THERAPEUTICS PLC
01/02 REALM THERAPEUTICS : Presents at 5th Annual Dermatology Summit
2017 REALM THERAPEUTICS : Director/PDMR Shareholding
2017 REALM THERAPEUTICS : First Patient Dosed in Phase 2 Study of PR013
2017 REALM THERAPEUTICS : Announces First Patient Dosed in Phase 2 Study of PR022 for..
2017 REALM THERAPEUTICS : First Patient Dosed in Phase 2 Study of PR022
2017 REALM THERAPEUTICS - REALM : Preclinical Data on PR022 Published
2017 REALM THERAPEUTICS : Directorate Change
2017 REALM THERAPEUTICS : Presents Data Highlighting PR013's Efficacy Reducing Hypere..
2017 REALM THERAPEUTICS : Realm Therapeutics to Present at BIO-Europe® 2017
2017 REALM THERAPEUTICS : Presents Data Highlighting PR013`s Efficacy Reducing Hypere..
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2016Just posted: PuriCore (#PURI) – $13.5m completion of disposal of supermarket .. 
2016Just posted: PuriCore (#PURI) – proposed $13.5m disposal of Supermarket retai.. 
2016PuriCore Successfully Completes Pre-IND Meeting With the FDA on PR022 for Ato.. 
2015#London #stocks: Puricore : #Merger #Acquisition Analysts say: skimpy Dec 201.. 
2015#London #stocks: Puricore : #Merger #Acquisition Analysts say: optimistic Aug.. 
More tweets
Qtime:4
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | PURI | GB00B3XBCR18 | 4-Traders
Technical analysis trends REALM THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Mark Sampson Vice President-Research & Development
Christian Peters Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC16.22%69
CELLTRION, INC.--.--%37 510
IQVIA HOLDINGS INC2.37%20 782
LONZA GROUP0.76%20 640
INCYTE CORPORATION-4.65%19 399
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 192